Pembrolizumab plus lenvatinib achieved a superior tumor response to axitinib-based regimens, whereas survival outcomes were comparable. Treatment selection should balance enhanced antitumor activity with differences in toxicity profiles.
Kobatake et al. (Wed,) studied this question.